Should I buy Cytokinetics (CYTK) stock or is it too late?

Cytokinetics · Health Care · price $78

See the full Cytokinetics (CYTK) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Mizuho — 64% of its targets hit on this sector (70 calls tested). It aims for $118 (+52 %), call made on June 25, 2026, maturing on June 25, 2027 (64 d ago).

The 4 reliable analysts $114+46 %

The 9 other firms $108+39 %

How to read it: the 4 reliable firms are not filtered by optimism — 4 aim above the price, 0 below, hence their $114 median. “The 9 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Cytokinetics

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Goldman Sachs	67 %	+52.5 %	6	$95 +22%
Cantor Fitzgerald	89 %	+52.0 %	9	$65 -17%
Morgan Stanley	71 %	+44.0 %	14	$103 +32%
Needham	63 %	+21.9 %	27	$112 +44%
HC Wainwright & Co.	69 %	+20.4 %	48	$140 +80%
JP Morgan	50 %	+19.4 %	6	$103 +32%
Mizuho	57 %	+19.2 %	7	$118 +51%
JMP Securities	53 %	+18.2 %	15	—

In short — Should you invest in Cytokinetics? Is it too late, still worth it? Analysts are overwhelmingly positive (100% buy, median target $110, i.e. +41%), and the most reliable on CYTK targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

100% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $110, i.e. +41% from the current price ($78).
The most reliable firm on CYTK, Citigroup (100% hit rate, 3 scored calls), targets $99 (call made on May 19, 2026, maturing on May 19, 2027) (+27%) in its most recent call, and $84 (call made on September 2, 2025, maturing on September 2, 2026) (+8%) in the one coming due soonest.

⚠️ Reasons to hesitate

A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.
A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.

The analyst consensus on CYTK

Median target $110 (+41%) · 13 ratings · Buy consensus

Strong Buy00%

Buy13100%

Hold00%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Cytokinetics now?

We won't decide for you. The facts: 100% of analysts rate it a buy, median target $110 (+41%), and Citigroup (most reliable on CYTK, 100%) targets $99. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Cytokinetics?

Not according to analysts: the median target ($110) is still +41% above the current price ($78) (most reliable on CYTK: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Cytokinetics still worth investing in?

It depends on the gap between the price ($78) and its estimated value: analysts target $110 on median (+41%), with 100% buys (most reliable on CYTK: Citigroup, 100%). Cross-check with their real reliability on CYTK and the cautions above. Information, not advice.

What's the main risk in buying CYTK?

A 12-month target is not a guaranteed path: the price can fall in the meantime.

→ Go deeper: the full Cytokinetics profile (consensus, analyst reliability, price target, performance).